Gilead Sciences reported a second-quarter 2026 adjusted loss of $6.75 per share, narrower than the Zacks Consensus Estimate of a loss of $7.07, while revenues increased 10% year over year to $7.80 billion, beating the consensus of $7.37 billion. HIV product sales rose 12% to $5.69 billion, driven by Biktarvy sales of $3.80 billion and Descovy sales of $967 million, along with $232 million from newly approved Yeztugo for PrEP. The company raised its full-year HIV sales growth guidance to 9-10% and now expects total product sales of $30.10 billion to $30.40 billion, up from the prior range. Trodelvy sales grew 26% to $457 million, while Cell Therapy sales declined 14% to $417 million amid competitive pressures. The adjusted loss primarily reflected $11.2 billion in acquired in-process research and development expenses related to the acquisitions of Arcellx, Tubulis and Ouro Medicines.
Gilead Sciences IncQ2 earnings beat estimates and raised 2026 product sales outlook
GSK plc
Merck & Company Inc